Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Exome-Wide Sequencing Reveals Oncogenic Mutations in Both Progressive and Non-Progressive MBL

Doreen te Raa, Mark Lanasa, MD PhD, Sallie Allgood, Paula Scotland, Cassie Love, Arend Jan van Houte, Douwe Biesma, Arnon P. Kater, MD PhD, Sandeep Dave, MD

Blood (2015) 126 (23): 361.

https://doi.org/10.1182/blood.V126.23.361.361

Published: 2015

Journal Articles

Next-Generation Sequencing Reveals Oncogenic Driver Mutations In Both Progressive and Non-Progressive Monoclonal B Lymphocytosis

Mark C. Lanasa, MD, PhD, Doreen te Raa, MD, Sallie D. Allgood, MS, Paula Scotland, PhD, Cassie Love, MS, Zhen Sun, MS, Arend Jan van Houte, PhD, Douwe Biesma, MD, PhD, Arnon P. Kater, MD PhD, Sandeep Dave, MD

Blood (2013) 122 (21): 1615.

https://doi.org/10.1182/blood.V122.21.1615.1615

Published: 2013

Journal Articles

Out of Hospital Treatment of Acute Pulmonary Embolism in Patients with a Low NT-ProBNP Level.

Mariette J Agterof, MD, Roger E.G. Schutgens, MD, PhD, Repke J Snijder, MD, G. Epping, MD, Henny G Peltenburg, MD, PhD, Ward Posthuma, MD, PhD, J. A. Hardeman, MD, Rene Van der Griend, MD, PhD, Ted Koster, Martin Prins, MD, PhD, Douwe Biesma, MD, PhD

Blood (2009) 114 (22): 3996.

https://doi.org/10.1182/blood.V114.22.3996.3996

Published: 2009

Journal Articles

Value of Additional CD19 Lymphocyte Counts for the Detection of B-CLL in a Primary Health Care Laboratory

Doreen te Raa, MD, Kathelijn Fischer, MD, PhD, Wim Verweij, Douwe Biesma, MD, PhD

Blood (2008) 112 (11): 4184.

https://doi.org/10.1182/blood.V112.11.4184.4184

Published: 2008

Journal Articles

Improving the Efficacy of Non-Radiologic Exclusion of Deep Venous Thrombosis in the Elderly Using the Thrombin Generation Assay

Fred JLM Haas, Roger EG Schutgens, Douwe Biesma, MD, PhD

Blood (2008) 112 (11): 3815.

https://doi.org/10.1182/blood.V112.11.3815.3815

Published: 2008

Journal Articles

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Pieter Sonneveld, MD, Wim van Putten, MsC, Douwe Biesma, MD, Harald Holte, MD, Marinus van Marwijk Kooij, MD, Mark Henri H. Kramer, MD, P.W. Wijermans, MD, Monique Steijaert, Gustaaf W. van Imhoff, MD, P.J. Lugtenburg, MD, P.C. Huijgens, MD, Mikael Eriksson, MD

Blood (2006) 108 (11): 210.

https://doi.org/10.1182/blood.V108.11.210.210

Published: 2006

Journal Articles

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Pieter Sonneveld, MD, Wim van Putten, MSc, Harald Holte, MD, Douwe Biesma, MD, Marinus van Marwijk-Kooy, MD, Mark Kramer, MD, Pierre Wijermans, MD, Monique Steijaert, Peter Huijgens, MD, Mikael Eriksson, MD

Blood (2005) 106 (11): 16.

https://doi.org/10.1182/blood.V106.11.16.16

Published: 2005

Journal Articles

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Updated Analysis of the Randomized Phase III Study HOVON 24 MM.

Pieter Sonneveld, Bronno van der Holt, Christine Segeren, Edo Vellenga, Reinier Raymakers, Gregor Verhoef, Ron Schaafsma, Marinus van Oers, Pierre Weijermans, Wim Fibbe, Shulamit Wittebol, Marinus van Marwijk, Douwe Biesma, Joke Baars, Harry Schouten, Petra Westveer, Monique Steijaert, Henk Lokhorst

Blood (2004) 104 (11): 948.

https://doi.org/10.1182/blood.V104.11.948.948

Published: 2004

NARROW

Exome-Wide Sequencing Reveals Oncogenic Mutations in Both Progressive and Non-Progressive MBL

Next-Generation Sequencing Reveals Oncogenic Driver Mutations In Both Progressive and Non-Progressive Monoclonal B Lymphocytosis

Out of Hospital Treatment of Acute Pulmonary Embolism in Patients with a Low NT-ProBNP Level.

Value of Additional CD19 Lymphocyte Counts for the Detection of B-CLL in a Primary Health Care Laboratory

Improving the Efficacy of Non-Radiologic Exclusion of Deep Venous Thrombosis in the Elderly Using the Thrombin Generation Assay

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Updated Analysis of the Randomized Phase III Study HOVON 24 MM.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only